Skip to main content
HEM Pharma Inc. logo

HEM Pharma Inc. — Investor Relations & Filings

Ticker · 376270 ISIN · KR7376270005 KO Manufacturing
Open in API
Filings indexed 93 across all filing types
Latest filing 2026-02-24 Regulatory Filings
Country KR South Korea
Listing KO 376270

About HEM Pharma Inc.

https://hempharma.bio/

HEM Pharma Inc. is a biotechnology company specializing in microbiome-based healthcare solutions. The company researches and develops Live Biotherapeutic Products (LBPs), health functional foods, and other bio-products derived from human-effective microbes. A core component of its R&D is the proprietary Pharmaceutical Meta-Analysis System (PMAS), a technology platform that simulates the human gut microbiome to screen for and analyze beneficial microorganisms. In addition to its product pipeline, HEM Pharma provides personalized healthcare services based on microbiome analysis and offers Contract Development and Manufacturing Organization (CDMO) services for next-generation biological materials.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) between HEM Pharma and its subsidiary. It details the contract value, duration, and counterparty. Since this is a specific regulatory announcement of a material business event (a contract award) that does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2026-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (HEM Pharma) announcing a significant change (over 30%) in revenue or profit/loss structure compared to the previous fiscal year. This is a standard disclosure requirement in the Korean stock market (KRX) for listed companies to provide preliminary financial results before the final audit. Since it provides key financial highlights and reasons for the variance, it falls under the 'Earnings Release' category. FY 2025
2026-02-20 Korean
파생상품거래손실발생
Capital/Financing Update Classification · 1% confidence The document is a regulatory disclosure regarding a 'Derivatives Trading Loss' (파생상품거래손실발생) filed by HEM Pharma. It details the nature of the loss, the impact on equity, and the accounting reasons (non-cash valuation loss on convertible bonds). As this is a specific regulatory disclosure of a material event that does not fit into financial reports, dividends, or management changes, it falls under the general regulatory filing category.
2026-02-20 Korean
기업설명회(IR)개최
Investor Presentation Classification · 1% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it fits the criteria for a regulatory notification of an IR activity, it is classified as a Report Publication Announcement (RPA) or general regulatory filing. Given the specific nature of announcing an IR event, RPA is the most accurate fit.
2026-01-26 Korean
기업설명회(IR)개최
Investor Presentation Classification · 1% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (a Non-Deal Roadshow). It provides details such as the date, location, purpose, and target audience for the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it does not fit into other specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure.
2026-01-22 Korean
기업설명회(IR)개최
Investor Presentation Classification · 1% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (a Non-Deal Roadshow). It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it is a regulatory notification of an IR activity, it falls under the category of a general regulatory filing or announcement regarding corporate activities.
2026-01-20 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.